ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
12 sept. 2023 06h30 HE
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”)This study showed that NLRP3...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
10 juil. 2023 07h37 HE
|
ZyVersa Therapeutics
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical...
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
28 juin 2023 07h37 HE
|
ZyVersa Therapeutics
Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damageNLRP3 inflammasomes were extensively activated in...
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
20 juin 2023 16h07 HE
|
ZyVersa Therapeutics
PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are...
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
13 juin 2023 08h07 HE
|
ZyVersa Therapeutics
White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich, and Robert W. Keane, University of Miami Miller School of...
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
25 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
04 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
25 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
10 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
01 mars 2023 09h20 HE
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...